William Blair Reconfirmed Krystal Biotech (KRYS) as Buy; Xbiotech (XBIT) Shorts Increased By 13.94%

XBiotech Inc. (NASDAQ:XBIT) Logo

Xbiotech Inc (NASDAQ:XBIT) had an increase of 13.94% in short interest. XBIT’s SI was 1.25M shares in March as released by FINRA. Its up 13.94% from 1.10M shares previously. With 293,500 avg volume, 4 days are for Xbiotech Inc (NASDAQ:XBIT)’s short sellers to cover XBIT’s short positions. The SI to Xbiotech Inc’s float is 6.24%. The stock decreased 2.15% or $0.21 during the last trading session, reaching $9.77. About 94,781 shares traded. XBiotech Inc. (NASDAQ:XBIT) has risen 90.53% since March 13, 2018 and is uptrending. It has outperformed by 86.16% the S&P500. Some Historical XBIT News: 16/04/2018 – XBIOTECH INC – CO WOULD EVALUATE A NEW SUBCUTANEOUS FORMULATION OF CO’S TRUE HUMAN MONOCLONAL ANTIBODY, MABP1, IN TWO SEPARATE PHASE 2 STUDIES; 22/05/2018 – XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis; 20/04/2018 – DJ XBiotech Inc, Inst Holders, 1Q 2018 (XBIT); 02/04/2018 – XBIOTECH – WILL USE ITS TECHNOLOGY TO ADVANCE DEVELOPMENT OF TRUE HUMAN(TM )ANTI-NY-ESO-1 MONOCLONAL ANTIBODY, 12D7; 02/04/2018 – XBIOTECH INC – HAS OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG; 02/04/2018 – XBIOTECH IN-LICENSES ANTI-NY-ESO-1 ANTIBODY FROM CT ATLANTIC; 02/04/2018 – XBIOTECH INC – OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG, A SWISS BIOTECHNOLOGY COMPANY; 16/04/2018 – Press Release: XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology; 02/04/2018 XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer; 16/04/2018 – XBIOTECH INC – UPCOMING PHASE 2 CLINICAL STUDIES IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) AND HIDRADENITIS SUPPURATIVA (HS)

Krystal Biotech Inc (KRYS) stock had its Buy Rating reiterated by equity analysts at William Blair in analysts report sent to investors on Wednesday, 13 March.

The stock decreased 4.23% or $0.89 during the last trading session, reaching $20.16. About 76,688 shares traded or 50.91% up from the average. Krystal Biotech, Inc. (KRYS) has risen 118.25% since March 13, 2018 and is uptrending. It has outperformed by 113.88% the S&P500.

More notable recent Krystal Biotech, Inc. (NASDAQ:KRYS) news were published by: Globenewswire.com which released: “Krystal Biotech Reports 2018 Financial Results and Business Progress – GlobeNewswire” on March 12, 2019, also Nasdaq.com with their article: “Krystal (KRYS) in Focus: Stock Moves 5.1% Higher – Nasdaq” published on March 07, 2019, Nasdaq.com published: “Krystal Strengthens Board of Directors with Appointment of Julian S. Gangolli – Nasdaq” on March 04, 2019. More interesting news about Krystal Biotech, Inc. (NASDAQ:KRYS) were released by: Nasdaq.com and their article: “Krystal Biotech to Present at the Cowen and Company 39th Annual Health Care Conference – Nasdaq” published on March 01, 2019 as well as Seekingalpha.com‘s news article titled: “Krystal Biotech: Institutional Ownership Is Swelling – Seeking Alpha” with publication date: February 22, 2019.

Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company has market cap of $290.89 million. The company’s lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease. It currently has negative earnings. It also engages in developing KB105, which is in preclinical studies to treat Lamellar Ichthyosis, which is an autosomal recessive disorder.

Among 3 analysts covering Krystal Biotech (KRYS), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Krystal Biotech has $50 highest and $32 lowest target. $41’s average target is 103.37% above currents $20.16 stock price. Krystal Biotech had 5 analyst reports since September 24, 2018 according to SRatingsIntel. H.C. Wainwright maintained the shares of KRYS in report on Wednesday, March 6 with “Buy” rating. The firm has “Buy” rating by Chardan Capital Markets given on Wednesday, March 6. The company was maintained on Monday, October 15 by H.C. Wainwright.

More important recent XBiotech Inc. (NASDAQ:XBIT) news were published by: Seekingalpha.com which released: “XBiotech up 4% premarket on positive bermekimab data – Seeking Alpha” on March 05, 2019, also Seekingalpha.com published article titled: “XBiotech up 13% on positive bermekimab data – Seeking Alpha”, Streetinsider.com published: “XBiotech (XBIT) Says Results from Phase 2 Clinical Trial of Bermekimab in Treatment of Atopic Dermatitis to be Presented at ADD – StreetInsider.com” on March 01, 2019. More interesting news about XBiotech Inc. (NASDAQ:XBIT) was released by: Seekingalpha.com and their article: “Key events next week – healthcare – Seeking Alpha” with publication date: February 22, 2019.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *